BCL-2 Dependence and ABT-737 Sensitivity in Acute Lymphoblastic Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Dec 7

PMID 18056841

Citations 113

Authors

Victoria Del Gaizo Moore

Krysta D Schlis

Stephen E Sallan

Scott A Armstrong

Anthony Letai

Affiliations

Soon will be listed here.

Abstract

Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.

Citing Articles

The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia.

Al-Hamaly M, Winter E, Blackburn J Cancer Biol Ther. 2025; 26(1):2460252.

PMID: 39905687 PMC: 11801350. DOI: 10.1080/15384047.2025.2460252.

Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.

Sergio I, Varricchio C, Squillante F, Cantale Aeo N, Campese A, Felli M Int J Mol Sci. 2024; 25(23).

PMID: 39684550 PMC: 11641392. DOI: 10.3390/ijms252312839.

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.

Luskin M, Shimony S, Keating J, Keating J, Winer E, Garcia J Blood Adv. 2024; 9(3):617-626.

PMID: 39546748 PMC: 11847096. DOI: 10.1182/bloodadvances.2024014405.

Enhancement of the Sensitivity of the Acute Lymphoblastic Leukemia Cells to ABT-737 by Formononetin.

Abbasi Y, Pooladi M, Nazmabadi R, Amri J, Abbasi H, Aghabeygi R Int J Mol Cell Med. 2024; 13(3):259-271.

PMID: 39493513 PMC: 11530950. DOI: 10.22088/IJMCM.BUMS.13.3.259.

A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.

Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J EJHaem. 2024; 5(5):951-956.

PMID: 39415930 PMC: 11474352. DOI: 10.1002/jha2.991.

References

van Delft M, Wei A, Mason K, Vandenberg C, Chen L, Czabotar P . The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006; 10(5):389-99. PMC: 2953559. DOI: 10.1016/j.ccr.2006.08.027. View

Hueber A, Evan G . Traps to catch unwary oncogenes. Trends Genet. 1998; 14(9):364-7. DOI: 10.1016/s0168-9525(98)01520-0. View

Hahn W, Weinberg R . Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002; 2(5):331-41. DOI: 10.1038/nrc795. View

Gaizo Moore V, Brown J, Certo M, Love T, Novina C, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007; 117(1):112-21. PMC: 1716201. DOI: 10.1172/JCI28281. View

Puthalakath H, Strasser A . Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002; 9(5):505-12. DOI: 10.1038/sj.cdd.4400998. View

Certo M, Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong S . Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006; 9(5):351-65. DOI: 10.1016/j.ccr.2006.03.027. View

Wang K, Yin X, Chao D, Milliman C, Korsmeyer S . BID: a novel BH3 domain-only death agonist. Genes Dev. 1996; 10(22):2859-69. DOI: 10.1101/gad.10.22.2859. View

Kelekar A, Thompson C . Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998; 8(8):324-30. DOI: 10.1016/s0962-8924(98)01321-x. View

Cleary M, Smith S, Sklar J . Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986; 47(1):19-28. DOI: 10.1016/0092-8674(86)90362-4. View

10.

Campos L, Sabido O, Sebban C, Charrin C, Bertheas M, Fiere D . Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia. 1996; 10(3):434-8. View

11.

McGill G, Horstmann M, Widlund H, Du J, Motyckova G, Nishimura E . Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002; 109(6):707-18. DOI: 10.1016/s0092-8674(02)00762-6. View

12.

Tahir S, Yang X, Anderson M, Morgan-Lappe S, Sarthy A, Chen J . Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007; 67(3):1176-83. DOI: 10.1158/0008-5472.CAN-06-2203. View

13.

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

14.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

15.

Mihara K, Imai C, Coustan-Smith E, Dome J, Dominici M, Vanin E . Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003; 120(5):846-9. DOI: 10.1046/j.1365-2141.2003.04217.x. View

16.

Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

17.

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

18.

Kaufmann S, Karp J, Svingen P, Krajewski S, Burke P, Gore S . Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998; 91(3):991-1000. View

19.

Wojcik I, Szybka M, Golanska E, Rieske P, Blonski J, Robak T . Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma. 2005; 52(4):318-24. View

20.

Haarman E, Kaspers G, Pieters R, van Zantwijk C, Broekema G, Hahlen K . BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance. Adv Exp Med Biol. 1999; 457:325-33. DOI: 10.1007/978-1-4615-4811-9_35. View